IGF1R and diffuse large B-cell lymphoma: Given that inhibition of IGF-1R restrained YAP expression and showed anti-tumor effects on DLBCL cells, our findings indicate that targeting IGF-1R activity may produce therapeutic value in DLBCL by restricting YAP activity, which raises the possibility that molecular therapies targeting YAP will provide an attractive precise treatment strategy for DLBCL.